Mucin overexpression limits the effectiveness of 5-FU by reducing intracellular drug uptake and antineoplastic drug effects in pancreatic tumours.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  European Journal of Cancer

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ejca.2008.10.008PMID 19046630
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bismuth-213 radioimmunotherapy with C595 anti–MUC1 monoclonal antibody in an ovarian cancer ascites model

  2008cited by this paper
• Cancer Statistics, 2008

  2008cited by this paper
• Mucin-type O-glycosylation and its potential use in drug and vaccine development.

  2008cited by this paper
• MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas

  2007cited by this paper
• Diffusion of nutrients molecules and model drug carriers through mucin layer investigated by magnetic resonance imaging with chemical shift resolution.

  2007cited by this paper
• Effects of tumour necrosis factor on human tumour xenografts in nude mice.

  2007cited by this paper
• Mucin impedes cytotoxic effect of 5-FU against growth of human pancreatic cancer cells: overcoming cellular barriers for therapeutic gain

  2007cited by this paper
• Mucin expression profile in pancreatic cancer and the precursor lesions.

  2007cited by this paper
• Diagnostic value of mucins (MUC1, MUC2 and MUC5AC) expression profile in endoscopic ultrasound‐guided fine‐needle aspiration specimens of the pancreas

  2007cited by this paper
• Medical treatment of pancreatic cancer

  2007cited by this paper
• Cell surface-associated mucins in signal transduction.

  2006cited by this paper
• Development of 5-FU and Doxorubicin-Loaded Cationic Liposomes against Human Pancreatic Cancer: Implications for Tumor Vascular Targeting

  2006cited by this paper
• Regulation of mucin expression: mechanistic aspects and implications for cancer and inflammatory diseases.

  2006influential reference
• RNA Interference Suppression of MUC1 Reduces the Growth Rate and Metastatic Phenotype of Human Pancreatic Cancer Cells

  2006cited by this paper
• Genetic and biochemical modulation of 5-fluorouracil through the overexpression of thymidine kinase: an in-vitro study

  2006cited by this paper
• Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.

  2005cited by this paper
• Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer

  2005cited by this paper
• MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas

  2005cited by this paper
• The Chemistry and Biology of Mucin‐Type O‐Linked Glycosylation

  2005cited by this paper
• The chemistry and biology of mucin-type O-linked glycosylation.

  2005cited by this paper
• Mucins in cancer: protection and control of the cell surface

  2004cited by this paper
• The Influence of Intestinal Mucus Components on the Diffusion of Drugs

  2004cited by this paper
• Secreted and Transmembrane Mucins Inhibit Gene Transfer with AAV4 More Efficiently than AAV5*

  2002cited by this paper
• Altered mucin expression in the gastrointestinal tract: a review

  2001cited by this paper
• Drug transfer through mucus.

  2001cited by this paper
• Experimental animal models of pancreatic cancer (review).

  2000cited by this paper
• Biological properties and expression of mucins in 5-fluorouracil resistant HT29 human colon cancer cells.

  2000cited by this paper
• Increased cytotoxicity and bystander effect of 5-fluorouracil and 5′-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase

  1999cited by this paper
• Mucus as a barrier to the permeability of hydrophilic and lipophilic compounds in the absence and presence of sodium taurocholate micellar systems using cell culture models.

  1999cited by this paper
• HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro-in vivo correlation with permeability data from rats and humans.

  1996cited by this paper
• Epithelial mucin genes.

  1995cited by this paper
• Expression of the cystic fibrosis gene and the major pancreatic mucin gene, MUC1, in human ductal epithelial cells.

  1993cited by this paper
• Uptake and distribution of specific and control monoclonal antibodies in subcutaneous xenografts following intratumor injection.

  1991cited by this paper
• Biochemical pharmacology and analysis of fluoropyrimidines alone and in combination with modulators.

  1991cited by this paper
• Growth adaptation to methotrexate of HT-29 human colon carcinoma cells is associated with their ability to differentiate into columnar absorptive and mucus-secreting cells.

  1990cited by this paper
• Fluorouracil: biochemistry and pharmacology.

  1988cited by this paper

• OGT-enriched hepatocyte-derived extracellular vesicles promote capillarization of liver sinusoidal endothelial cells in metabolic dysfunction-associated steatotic liver disease.

  2026cites this paper
• Mutational signatures in appendiceal adenocarcinomas: potential for future personalization in hyperthermic intraperitoneal chemotherapy?

  2025cites this paper
• Overcoming therapy resistance in pancreatic cancer: challenges and emerging strategies.

  2025cites this paper
• Post-translational modifications in drug resistance.

  2024cites this paper
• MUC1 promotes cervical squamous cell carcinoma through ERK phosphorylation-mediated regulation of ITGA2/ITGA3

  2024cites this paper
• Influence of glycosylation on the development and treatment of neuroblastoma.

  2023cites this paper
• Advances in the Evaluation of Gastrointestinal Absorption Considering the Mucus Layer

  2023cites this paper
• Advances in MUC1 resistance to chemotherapy in pancreatic cancer

  2023cites this paper
• Development of [225Ac]Ac-DOTA-C595 as radioimmunotherapy of pancreatic cancer: in vitro evaluation, dosimetric assessment and detector calibration

  2023cites this paper
• Drug Resistance in Cancers: A Free Pass for Bullying

  2022cites this paper
• Current Nano-Strategies to Improve Therapeutic Efficacy Across Special Structures

  2022cites this paper
• The Glycosylated N-Terminal Domain of MUC1 Is Involved in Chemoresistance by Modulating Drug Permeation Across the Plasma Membrane

  2022cites this paper
• Identification of Candidate Therapeutic Genes for More Precise Treatment of Esophageal Squamous Cell Carcinoma and Adenocarcinoma

  2022cites this paper
• Altered glycosylation in pancreatic cancer and beyond

  2022cites this paper
• MUC1: Structure, Function, and Clinic Application in Epithelial Cancers

  2021cites this paper
• MUC4 enhances gemcitabine resistance and malignant behaviour in pancreatic cancer cells expressing cancer-associated short O-glycans.

  2021cites this paper
• Mucins reprogram stemness, metabolism and promote chemoresistance during cancer progression

  2021cites this paper
• M2 Macrophages Infiltrating Epithelial Ovarian Cancer Express MDR1: A Feature That May Account for the Poor Prognosis

  2020cites this paper
• Mucins in pancreatic cancer: A well‐established but promising family for diagnosis, prognosis and therapy

  2020cites this paper
• MUC glycoproteins: Potential biomarkers and molecular targets for cancer therapy.

  2020cites this paper
• Slippery Nanoparticles as a Diffusion Platform for Mucin Producing Gastrointestinal Tumors

  2019cites this paper
• Bacterial biofilms as a potential contributor to mucinous colorectal cancer formation.

  2019cites this paper
• LINC01296/miR-26a/GALNT3 axis contributes to colorectal cancer progression by regulating O-glycosylated MUC1 via PI3K/AKT pathway

  2018cites this paper
• Physicochemical properties of mucus and their impact on transmucosal drug delivery.

  2017cites this paper
• RNA interference-mediated silencing of ppGalNAc-T1 and ppGalNAc-T2 inhibits invasion and increases chemosensitivity potentially by reducing terminal α2,3 sialylation and MMP14 expression in triple‑negative breast cancer cells.

  2017cites this paper
• Drug resistance related to aberrant glycosylation in colorectal cancer

  2017cites this paper
• Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus

  2017cites this paper
• Development of a targeted Drug Delivery System for treatment of Pancreatic Ductal Adenocarcinom

  2017cites this paper
• Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine

  2017cites this paper
• Development and In Vitro Characterization of a Gemcitabine-loaded MUC4-targeted Immunoliposome Against Pancreatic Ductal Adenocarcinoma.

  2017cites this paper
• Mucins in pancreatic cancer: biological role, implications in carcinogenesis and applications in diagnosis and therapy.

  2017cites this paper
• RNA interference ‐ mediated silencing of ppGalNAc ‐ T 1 and ppGalNAc ‐ T 2 inhibits invasion and increases chemosensitivity potentially by reducing terminal α 2 , 3 sialylation and MMP 14 expression in triple ‐ negative breast cancer cells

  2017cites this paper
• Targeting MUC16 in Cancer Therapy

  2017cites this paper
• MUC5B silencing reduces chemo-resistance of MCF-7 breast tumor cells and impairs maturation of dendritic cells.

  2016cites this paper
• Molecular Pathways: Mucins and Drug Delivery in Cancer

  2016influential citation
• The promise of protein glycosylation for personalised medicine.

  2016cites this paper
• Small-Molecule Inhibition of GCNT3 Disrupts Mucin Biosynthesis and Malignant Cellular Behaviors in Pancreatic Cancer.

  2016cites this paper
• Investigating the role of mucin in the delivery of nanoparticles to cellular models of human cancer disease: an in vitro study.

  2016cites this paper
• Clinical relevance of the differential expression of the glycosyltransferase gene GCNT3 in colon cancer.

  2015cites this paper
• MUC1 as a Potential Target in Anticancer Therapies

  2015cites this paper
• The MUC1 oncomucin regulates pancreatic cancer cell biological properties and chemoresistance. Implication of p42-44 MAPK, Akt, Bcl-2 and MMP13 pathways.

  2015cites this paper
• Mucins and tumor resistance to chemotherapeutic drugs.

  2014influential citation
• Efficacy of a novel mucolytic agent on pseudomyxoma peritonei mucin, with potential for treatment through peritoneal catheters.

  2014cites this paper
• The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression

  2013cites this paper
• Integrated Surface and Mechanical Characterization of Freestanding Biological and Other Nano-Structures Using Atomic Force Microscopy

  2013influential citation
• ONCOLYTIC VESICULAR STOMATITIS VIRUS IN IMMUNOCOMPETENT MODEL OF 1 MUC 1 POSITIVE AND MUC 1 NULL PANCREATIC DUCTAL ADENOCARCINOMA 2 3 Running Title : “ VSV IN AN IMMUNOCOMPETENT MODEL OF PANCREATIC 4 CANCER ”

  2013cites this paper
• Oncolytic Vesicular Stomatitis Virus in an Immunocompetent Model of MUC1-Positive or MUC1-Null Pancreatic Ductal Adenocarcinoma

  2013cites this paper
• Anticancer Property of Bromelain With Therapeutic Potential in Malignant Peritoneal Mesothelioma

  2013cites this paper
• The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family

  2013cites this paper
• Mucin-based targeted pancreatic cancer therapy.

  2012cites this paper
• Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.

  2012cites this paper
• Molecular targeted approaches for treatment of pancreatic cancer.

  2011cites this paper
• Evaluation of Mucin Glycosylation as a barrier to drug uptake : a quantitative approach.

  2010influential citation
• Synthesis, Structure and Anticancer Activity Studies of 1-[(5-Bromo-2-thienyl)sulfonyl] -5-fluoro-1,2,3,4-tetrahydropyrimidine-2,4-dione.

  2010cites this paper
• Mucin 21/Epiglycanin Modulates Cell Adhesion

  2010cites this paper
• Mucins and Pancreatic Cancer

  2010cites this paper
• Glycoprotein mucin molecular brush on cancer cell surface acting as mechanical barrier against drug delivery

  2010cites this paper
• The membrane-bound mucins: how large O-glycoproteins play key roles in epithelial cancers and hold promise as biological tools for gene-based and immunotherapies.

  2008cites this paper